{
    "nct_id": "NCT06879041",
    "official_title": "A Phase I, First-in-human, Dose Escalation Study Of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer",
    "inclusion_criteria": "* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n* Histologically confirmed diagnosis of adenocarcinoma of the prostate or neuroendocrine differentiated prostate cancer.\n* Must have had prior bilateral orchiectomy and/or ongoing androgen-deprivation therapy and a castrate level of serum/plasma testosterone (< 50 ng/dL or < 1.7 nmol/L).\n* At least one metastatic lesion present on baseline Computed Tomography (CT), Magnetic Resonance Imaging (MRI), or bone scan obtained ≤ 28 days prior to the first dose of Investigational Medicinal Product (IMP). Participants may have non-measurable lesions including bone only metastases.\n* Adequate organ function\n\nMain\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Treatment with any radiopharmaceutical within 6 weeks of the first dose of Investigational Medicinal Product (IMP).\n* Radiation therapy (RT) within 28 days prior to the first dose and all RT-related events have not recovered to Grade ≤ 1.\n* Administration of any systemic cytotoxic or investigational therapy ≤ 28 days of the first dose of IMP or 5 half-lives, whichever is shorter.\n* All prior treatment-related adverse events must have resolved to Grade ≤ 1.\n* Concurrent severe and/or uncontrolled illness not related to cancer and/or social situation that would limit compliance with study requirements.\n* Known or suspected allergies or contraindications to any of the investigational drugs or any component of the investigational drug formulation.\n* Clinically relevant proteinuria",
    "miscellaneous_criteria": "Main"
}